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A B S T R A C T  
Objective: To see the effect of febuxostat in slowing the progression that treatment with febuxostat improves eGFR in 
renal transplant recipients having asymptomatic hyperuricemia. 
Patients and Methods: This randomized controlled trial was carried out in a Department of Nephrology PIMS. A total of 
106 post renal transplants recipients having asymptomatic hyperuricemia, were randomly divided into two groups of 53 
each by lottery method. One group was given febuxostat for treatment of post renal transplant hyperuricemia while the 
other one was given a placebo. 
Results: The mean age of patients was 48.15 years with a male to female ratio 4.6:1. Treatment with febuxostat was 
linked significantly in lowering the mean uric acid level at 7.01mg/dl, 6.32mg/dl and 5.42mg/dl at 2, 4 and 6 months, 
respectively, and renal function was better preserved in the patients receiving febuxostat at mean eGFR of 49.74, 48.96 
& 48.89 ml/min/1.73m 2 at 2, 4 and 6 months, respectively. 
Conclusion: In patients with postrenal transplant asymptomatic hyperuricemia, febuxostat showed significant reduction 
in serum uric acid level with preservation of renal function. 
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I n t r o d u c t i o n  
 
Uric acid is a weak Acid Trioxypurine, comprising of 
imidazole and pyrimidine substructure with molecules of 
oxygen. It is made from metabolic conversion of either 
endogenous or dietary purines mainly in intestines, 
muscles and liver 1. Xanthine is the predecessor of uric 
acid which is metabolized into uric acid by the enzyme 
xanthine oxidoreductase i.e., xanthine-oxidase or 
xanthine dehydrogenase.2 Uric acid is mainly excreted by 
kidneys approx. 250-750 mg/day, which is about 70% of 
daily urate production.3 Post renal transplant 
hyperuricemia is defined as serum uric acid level 
>7.0mg/dl in men and >6.0mg/dl in women, having renal  
transplantation.4 Identification of new risk factors help in 
improvement of long-term outcomes. Numerous factors 
predisposing renal transplant recipients to hyperuricemia 
were reported, including treatment with diuretics, 
insufficient allograft function and immunosuppression with 
cyclosporine.5  
Asymptomatic hyperuricemia is a risk factor for 
cardiovascular disease and for the onset and progression 
of chronic kidney disease in general population.6,7 Chung 
et al investigated whether early-onset hyperuricemia has 
clinical importance irrespective of graft function.8 Post 
renal transplant hyperuricemia is linked with the onset of  
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cardiovascular disease and allograft loss in renal  
transplant recipients.9,10 Numerous studies have been 
done in kidney transplant recipients to assess the role of  
hyperuricemia in decreased renal function, but there has 
been a controversy in the results. The commonly used 
hypouricemic agents used in general population are 
Allopurinol and Benzbromarone but both of them cannot 
be used in post renal transplant hyperuricemia because of 
toxicity of the former and reduced hypouricemic effect due 
to chronic renal insufficiency and renal transplantation in 
the latter.11 Febuxostat is a non-purine selective inhibitor 
of xanthine oxidase and is better tolerated in patients with 
gout and/or moderate renal dysfunction.12,13 Metabolism 
of Febuxostat is mainly done by glucuronide formation 
and oxidation in the liver.14 However, the assessment of 
efficacy of febuxostat in kidney transplant recipients with 
asymptomatic hyperuricemia has not been done in local 
population so far. 
*Chi-square test and independent sample t-test, observed 
difference was statistically insignificant 
P a t i e n t s  a n d  M e t h o d s  
It is a prospective randomized controlled trial conducted in 
Department of Nephrology, Pakistan Institute of Medical 
Sciences, Islamabad, Pakistan over 6 months i.e., from 
18th September 2017 to 17th March, 2018.  Sample size 
was calculated using WHO sample size calculator. In total 
106 patients (87 males and 19 females), selected by non-
probability, consecutive sampling, were enrolled, and after 
informed consent were divided into 2 groups of 53 each, 
using lottery method. All renal transplant recipients with 
age from 20-60 years in PIMS nephrology OPD or ward, 3 
months’ post-transplantation with asymptomatic 
hyperuricemia, males having serum uric acid of >7.0 
mg/dl and females having serum uric acid level > 6mg/dl, 
eGFR > 35ml/min/1.73m 2, patients with cyclosporine 
levels in therapeutic range and, no previous history of 
gout. Group A was given febuxostat with adjusted dose 
according to individual eGFR of the participant using 
MDRD study equation. Group B was given placebo. 
Determination of serum uric acid levels and eGFR was 
done in both the groups at 2, 4 and 6 months and then 
both serum uric acid levels and eGFR were compared in 
both the groups at 2, 4 and 6 months. Nephrotoxic drugs 
were avoided in this time period. Patients with 
malignancy, hypersensitivity to febuxostat, already on any 
of the following drugs; probenicid, benzbromarone, 
fenofibrate, diuretics or azathioprine, patients having ALT 
and AST more than twice the upper limit of laboratory 
reference range, pregnancy and patients non-compliant to 
protein diet. 
R e s u l t s  
The mean age of the patients was 48.15±8.61 years, 
having 87 (82.1%) males and 19 (17.9%) female patients, 
with a male is to female ratio of 4.6:1. Demographic 
characteristic are presented in (Table 1). Treatment with 
febuxostat was linked with significant lowering of mean 
serum uric acid level at 2 months (7.01±0.35 mg/dl vs 
8.69±0.74 mg/dl; p < 0.001), at 4 months (6.32 ±0.33 
mg/dl vs 8.78 ± 0.78 mg/dl; p < 0.001) and at 6 months 
(5.42 ± 0.28 mg/dl vs 8.58 ± 0.72 mg/dl; p<0.001). It 
preserved renal function, which was evident from 
significantly higher mean eGFR with febuxostat at 2 
months (49.74 ± 4.67 ml/min/1.73m2 vs 47.34 ± 5.10 
ml/min/1.73m2; p<0.013), at 4 months (48.96 ± 4.88 
ml/min/1.73m2 vs 43.00 ±5.43 ml/min/1.73m2; p < 0.001) 
and at 6 months (48.89 ± 4.72 ml/min/1.73m2 vs 40.92 ± 
4.99 ml/min/1.73m2; p < 0.001) as compared with placebo 
(Table 2). 
Table 1: Baseline and Demographic Characteristics of 
Study Groups (n=106) 
Characteristics Group A 
Febuxostat 
(n=53) 
Group B 
Placebo 
(n=53) 
P 
value 
Age (years) 48.38 ±8.61 47.92 ±8.70 0.788 
<45 years 22 (41.5%) 23 (43.4%) 0.844 
≥45 years 31 (58.5%) 30 (56.6%) 0.844 
Gender    
Male 43 (81.1%) 44 (83.0%) 0.800 
Female 10 (18.9%) 9 (17.0%) 0.800 
Weight (Kg) 98.66 ±12.56 97.91 ±11.79 0.750 
Serum creatinine 
(mg/dl) 
1.84 ±0.27 1.85 ±0.35 0.912 
eGFR using 
MDRD equation 
(ml/min/1.73m2) 
50.38 ±5.23 50.13 ±5.10 0.807 
Serum Uric Acid 
(mg/dl) 
8.83 ±0.71 8.80 ±0.70 0.812 
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Table 2: Comparison of Various Laboratory Parameters between the Groups over 2, 4 and 6 Months Follow-
up (n=106) 
Lab Parameter Characteristic 0 2 months 4 months 6 months P value 
Serum creatinine(mg/dl) 
 Febuxostat 1.84±0.27 1.87±0.28 1.88±0.32 1.91±0.29 0.487 
 Placebo 1.85±0.35 1.99±0.35 2.05±0.30 2.25±0.38 0.006* 
 P value 0.912 0.070 0.005* <0.001*  
eGFR (ml/min/1.73m2) 
 Febuxostat 50.38±5.23 49.74±4.67 48.96±4.88 48.89±4.72 0.788 
 Placebo 50.13±5.10 47.34±5.10 43.00±5.43 40.92±4.99 0.028* 
 P value 0.807 0.013* <0.001* <0.001*  
Serum Uric Acid (mg/dl) 
 Febuxostat 8.83±0.71 7.01±0.35 6.32±0.33 5.42±0.28 <0.001* 
 Placebo 8.80±0.70 8.69±0.74 8.78±0.78 8.58±0.72 0.207 
 P value 0.812 <0.001* <0.001* <0.001*  
Independent sample t-test, *observed difference was 
statistically significant 
D i s c u s s i o n  
In order to improve long-term outcomes of kidney 
transplantation, new risk factors are required to be 
recognized that result in poor outcomes.5 Post- transplant 
hyperuricemia occurs in renal transplant recipients.4 Uric 
acid lowering drugs help to control serum uric acid levels 
and improve graft function.14-17 However, the available 
evidence contains controversy. Moreover, there was no 
such local published data available that triggered the 
need for this study. 
We observed that in patients on febuxostat, serum 
creatinine level gradually increased over 6 months but the 
difference was statistically insignificant.  Our results are 
comparable to those of Tojimbara et al, who also reported 
similar insignificant difference in mean serum creatinine in 
renal transplant patients with asymptomatic hyperuricemia 
on febuxostat treatment over 3 to 6 months’ interval from 
baseline.14 Oh et al also reported similar insignificant rise 
in creatinine in such patients over 6 months.16 eGFR 
decline in our study was also statistically insignificant. 
However, in present study, we found that treatment with 
febuxostat in post renal transplant recipients lead to 
significant reduction in serum uric acid level over 2, 4 and 
6 months’ follow-up from baseline, (8.83±0.71 mg/dl vs. 
7.01 ±0.35 mg/dl vs. 6.32 ±0.33 mg/dl vs. 5.42 ±0.28 
mg/dl; p<0.001). Our observations are in line with  
 
Tojimbara et al, who also observed similar decline in 
serum uric acid levels in patients with post renal 
transplant hyperuricemia recipients treated with 
febuxostat over 3 and 6 months (8.0 ±0.8 vs. 6.3 ±0.9 vs. 
5.7 ±0.7 mg/dl).14 Similar reduction in mean serum uric 
acid level has been reported by Sofue et al (8.4 0.3 vs. 
6.2 0.3 vs. 6.4 0.3 vs 6.2 0.3 mg/dl; p<0.05) after 1, 3 and 
6 months of treatment.15 
C o n c l u s i o n  
The present study indicates that patients with 
asymptomatic hyperuricemia after 3 months of renal 
transplantation, febuxostat treatment was linked with 
significant decrease in serum uric acid level with 
preservation of renal function evident from insignificant 
difference in the mean eGFR. The present study is the 
first of its kind in local population and advocates the 
routine use of febuxostat in hyperuricemic post renal-
transplant recipients. A very strong limitation to the 
present study was limited follow-up of 6 months. 
Consequently, long term results of febuxostat treatment 
on serum uric acid and kidney function were not 
considered. Studies involving long term follow-up are 
recommended in future research. 
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